Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
(incobotulinumtoxinA)
346 results
  • Therapy of Sialorrhea with Botulinum Neurotoxin. [Review]
    Neurol Ther 2019Jost WH, Bäumer T, … Bavikatte G
  • Botulinum neurotoxin (BoNT) is considered the treatment of choice for various symptoms and diseases such as focal dystonia and focal spasticity. The effects of BoNT on the salivary glands have also been known for years, but their use was limited because of a lack of approval studies. Now the indication of sialorrhea is approved in some countries for incobotulinumtoxinA, such as the USA and Europe…
  • Adverse Event Profiles of High Dose Botulinum Toxin Injections for Spasticity. [Journal Article]
    PM R 2019Kirshblum S, Solinsky R, … Botticello A
  • CONCLUSIONS: Risk for adverse events were not significantly increased in doses of ona- and/or incobotulinumtoxinA up to 600 units, suggesting that the current 400 units upper bound of approved dose may need to be reexamined. Doses above 600 units were found to increase the rate of adverse effects and clinical benefit versus risk should be taken into account.
  • Drugs and Lactation Database (LactMed): IncobotulinumtoxinA [BOOK]
    National Library of Medicine (US): Bethesda (MD)BOOK
  • No data exist on the medical use of incobotulinumtoxinA during breastfeeding. However, one infant was safely breastfed during maternal botulism and no botulinum toxin was detectable in the mother's milk or infant. Since the doses used medically are far lower than those that cause botulism, amounts ingested by the infant, if any, are expected to be small and not cause any adverse effects in breast…
  • IncobotulinumtoxinA and Deep Brain Stimulation. [Journal Article]
    Can J Neurol Sci 2019; 46(5):603-606Soh D, Fasano A
  • Guidelines recommend Botulinum toxin-A (BoNT-A) after deep brain stimulation (DBS), although the effectiveness of their combined use is uncertain. A chart review of Parkinson's disease (17) and dystonia (7) patients undergoing 302 injections with IncobotulinumtoxinA before or after DBS was performed. Patients with cervical dystonia received less IncobotulinumtoxinA after DBS (290.7 ± 124.0 vs. 19…
  • Do complexing proteins provide mechanical protection for botulinum neurotoxins? [Journal Article]
    J Neural Transm (Vienna) 2019; 126(8):1047-1050Dressler D, Pan L, … Bigalke H
  • Botulinum toxin (BT) consists of botulinum neurotoxin and complexing proteins (CPs). CPs might provide mechanical protection for botulinum neurotoxin. As incobotulinumtoxinA (INCO, Xeomin®) does not contain CPs, we wanted to compare its mechanical stability to that of onabotulinumtoxinA (ONA, Botox®) containing CPs. For this, ONA and INCO were reconstituted without mechanical stress (NS) and with…
New Search Next